Irritable Bowel Syndrome

Stomach pain
#EnteroBiotix #Gastroenterology #Irritable Bowel Syndrome #UK

EnteroBiotix secures £19m to advance IBS treatment 

EnteroBiotix has announced it has secured £19 million ($26 million) in financing to advance a treatment for irritable bowel syndrome.  The biopharmaceutical company is set to use the investment to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic. EBX-102-02 will be advanced into Phase IIb development for… Read More

#Business & Investment #News

Microbiome
#Clinical trials #Drug discovery #Irritable Bowel Syndrome #Microbiome

EnteroBiotix announces positive results for IBS microbiome therapy  

Biopharmaceutical company EnteroBiotix has announced positive final results from its  TrIuMPH clinical trial, which is evaluating the company’s full-spectrum microbiome therapeutic for patients with irritable bowel syndrome with constipation (IBS-C) with constipation or diarrhoea (IBS-D).  The Phase IIa clinical trial included 122 UK patients and results show that EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score (IBS-SSS) versus placebo. Read More

#News

Microbiome
#Clinical trials #EnteroBiotix #Gut microbiome #Irritable Bowel Syndrome

New positive microbiome results for IBS-C

EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class drugs for gut health, has announced positive initial results with EBX-102-02, the company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase IIa clinical trial in adults with irritable bowel syndrome with constipation (IBS-C). The multicentre, randomised, double-blind, placebo-controlled TrIuMPH (Treating IBS with an… Read More

#News

Stomach pain
#Chronic pain #Irritable Bowel Syndrome #Painkillers #Peptides #University of Queensland

Highly promising new oral approach to abdominal pain

University of Queensland (UQ) researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin. The team changed the chemical structure of oxytocin to make it gut-stable after earlier work revealed the hormone could treat… Read More

#News #Trending News

Gut microbiome
#EnteroBiotix #Gut microbiome #Irritable Bowel Syndrome #Microbiome #Phase II trial

Microbiome drug to be tested in IBS clinical trial

EnteroBiotix, a Glasgow, UK based biotechnology company, has dosed the first patient in a clinical trial designed to evaluate EBX-102-02 for the treatment of irritable bowel syndrome (IBS). The Phase II study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol… Read More

#News

#AI / data analytics / healthtech / informatics #Collaboration #Irritable Bowel Syndrome

Can an AI-driven data sharing effort advance IBD treatments? 

Iterative Scopes, provider of precision medicine technologies for gastroenterology, has entered into a data sharing agreement with Pfizer to accelerate the development of potential new treatments for patients suffering from IBD by standardising endoscopic interpretation.  Context  Currently, disease severity scoring systems, such as the Mayo Endoscopic… Read More

#News

Stomach pain
#Clinical trials #Irritable Bowel Syndrome #Microbiome

4D Pharma presents microbiome analyses from IBS Phase II clinical trial 

4D Pharma, a pharmaceutical company developing Live Biotherapeutic products (LBPs), has announced new faecal microbiome analyses from the completed Phase II trial of Blautix(R) (MRx1234) as a treatment for irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The new data was presented in an ePoster at Gastro 2021, held from December 9-11, 2021. … Read More

#News

#Irritable Bowel Syndrome #Microbiome

Clinical trials enable breakthrough treatment of IBS 

Enbiosis has made breakthrough in the treatment of irritable bowel syndrome (IBS), with 78% of the IBS patients who followed microbiome-based diets seeing symptoms improve dramatically.   Dr. Tarkan Karakan, a gastroenterology specialist who helped conduct the study, said: “We believe this achievement represents a significant step towards demonstrating… Read More

#News

#Clinical trial #Gastroenterology #Irritable Bowel Syndrome #Pharma

4D pharma new data for treatment of irritable bowel syndrome

4D pharma has released additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, by Professor Eamonn… Read More

#News